More Foreign than Neo: Harnessing the Power of Viral CMV Antigens in Cancer Vaccines

Mar 30th 2016
Forward-Looking Statement Disclaimer

This presentation contains forward-looking statements within the meaning of the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent, or cure any disease. The statements contained in this presentation regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our SEC periodic filings. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise. NO OFFER; NO RELIANCE. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any security and may not be relied upon in connection with the purchase or sale of any security. Any such offer would only be made by means of formal documents, the terms of which would govern in all respects. You should not rely on this presentation as the basis upon which to make any investment decision.

NASDAQ: VBIV
Company Overview

VBI VACCINES INC. (NASDAQ: VBIV) IS DEVELOPING NOVEL TECHNOLOGIES THAT SEEK TO EXPAND VACCINE PROTECTION IN SIGNIFICANT MARKETS OF UNMET MEDICAL NEED

• VBI is developing two complementary vaccine platform technologies:
  
  o **Enveloped Virus-like Particle ("eVLP") Platform:**
    - Prophylactic CMV Vaccine (Lead Candidate)
    - GBM Immunotherapy
    - Prophylactic RSV Vaccine
  
  o **Lipid Particle Vaccine ("LPV") Platform:** Proprietary formulation technology enables development of vaccines with preserved stability and potency
    - Active collaborations with Sanofi Pasteur & GSK to stabilize pipeline assets

• Headquartered in Cambridge, MA with its main research site in Ottawa, Canada
eVLP Platform: Potent Antigen Delivery
Virus-like Particle Vaccine Innovation

Early VLPs vs Capsid Virions were a Tremendous Success

• Nature
  o HPV Virion
  o Structure dominated by L1 capsid protein

• Viral Mimic
  o Merck & GSK succeed in a near perfect viral mimic
  o L1 = Major antigenic target AND structural determinant

Virus-like Particle Vaccine Innovation

Translation to Enveloped Viruses has been Challenging

• Nature
  o Enveloped virions share three key features
  o Glycoprotein antigens do not natively dictate particle structure

• Viral Mimic
  o VBI eVLPs mimic key elements of enveloped viruses
  o Glycoprotein antigens find a “native like” home in lipid bilayer
  o T-cell antigens can be fused in-frame with protein capsid core

eVLP Production: Multiple Genes and Cell Line Deliver Antigens in Natural Conformations: Within a membrane or internally

Flexible, Customized Antigen Delivery in a Biologically Relevant Construct

- “e” VLP Key Attributes
  - Antigen presented in Virus-like Structure (common to all VLPs)
  - MLV capsid protein creates virus like structure (unique)
  - Lipid membrane derived from production cell line (unique)
  - Envelope glycoproteins presented in lipid membrane as in nature (unique)
  - Internal proteins favor cellular (CTL) immune responses
Antigen Presentation in eVLP Improves Potency

Presentation of gB antigen in an eVLP improves relevant functional CMV neutralizing responses relative to recombinant gB protein.

PRECLINICAL RESULTS

- Structure of the eVLP platform generates stronger neutralizing antibodies than does immunization with recombinant gB
- Proprietary modification of transmembrane domain further improves eVLP potency
- No adjuvant included
eVLP Application to Immuno-Oncology
Cancer Immunity Cycle:

Potent, "Foreign" Antigen Presentation is Critical to the Solution

1) Antigen Presentation (or Steering)
Examples:
Positive: Vaccines
Negative: CD40

2) Priming & Activation (or GAS)
Examples:
Positive: GM-CSF, STING
Negative: CTLA-4

3) Migration & Infiltration (or GPS & Traffic Control)
Examples:
Positive: TILs
Negative: T-Regs, MDSC

4) Recognition & Killing (Checkpoints = Brakes):
Examples:
Positive: IFN-γ
Negative: PD1

CAR-T: elements of gas & steering
NeoAntigens – Increased Mutation Rates (“Foreign-ness”) Provides Immune System with Target for Clearance of Invasion

Checkpoint Blockade Effective Against “Hot’, Inflamed, High-mutation Rate Tumors with a Tapestry of Novel Antigens

Fig. 2. Estimate of the neoantigen repertoire in human cancer. Data depict the number of somatic mutations in individual tumors. Categories on the right indicate current estimates of the likelihood of neoantigen formation in different tumor types. Adapted from (50). It is possible that the immune system in melanoma patients picks up on only a fraction of the available neoantigen repertoire, in which case the current analysis will be an underestimate. A value of 10 somatic mutations per Mb of coding DNA corresponds to ~150 nonsynonymous mutations within expressed genes.
Traditional Tumor-Associated ("Self") Antigens (TAAs) are Poorly Immunogenic, Newer Mutations ("NeoAntigens") More Promising...

... BUT, NOTHING CAN BE AS FOREIGN AS A VIRAL ANTIGEN

- Immune system exists to fight foreign antigens
- Most successful cancer vaccines (HBV, HPV) are directed against viral targets
- Debating causality (HPV, CMV, EBV) misses the point!
  - Antigen expressed + Antigen is foreign = IDEAL TARGET!!
Evidence for CMV as a Target Antigen in GBM

Immuno-histochemical Staining of CMV in GBM Samples

C: negative control Ab
E: pp65 stained GBM sample

Primary GBM Tumors Present Antigens Recognized by CMV Specific T-cells

A

CMV pp65 effectors

Targets
- DC-pp65 RNA
- DC-survivin RNA
- DC-Flu M1 RNA
- DC-GBM tumor RNA
- DC-total cellular RNA
- GBM tumor cells

Nair SK(2014)
Evidence for CMV as a Target Antigen in GBM

Recent Clinical Evidence: CMV DC Vaccination Extends Survival\(^1\)

- DC priming + CMV DC vaccination increased OS of GBM patients
- Overall survival (>36.6 months) vs. control cohort with median OS of 18.5 months

Even Among Viral Antigens: CMV Highly Immunogenic & Highly Expressed in Solid Tumors

- CMV stimulates powerful immunity – 1-2% of circulating T-cells in infected individuals\(^2\)
- CMV is highly expressed (> 90%) on multiple solid tumors:
  - Glioblastoma (GBM)\(^3\)
  - Medulloblastoma\(^4,5\)
  - Meningioma\(^5\)
  - Breast cancer\(^6,7\)

## Design of GBM CMV eVLP Vaccine Candidate

### Rationale for vaccine components/mechanisms of action

<table>
<thead>
<tr>
<th>Vaccine Component</th>
<th>Immune Response</th>
<th>Scientific Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMV gB</td>
<td>Anti-gB Antibodies</td>
<td>• Prevent gB activation of GBM survival signals (Cobbs C et al, 2014)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Antibody-dependent cell cytotoxicity (ADCC)</td>
</tr>
<tr>
<td>CMV pp65</td>
<td>Polyvalent T-cell Responses:</td>
<td>• CMV pp65 DC vaccination prolongs overall survival of GBM patients (Mitchell DA et al, 2015)</td>
</tr>
<tr>
<td></td>
<td>CD4⁺ &amp; CD8⁺</td>
<td>• Responses against multiple epitopes and antigens (gB &amp; pp65) avoid immunoselection/tumor escape</td>
</tr>
<tr>
<td>eVLP formulation with GM-CSF</td>
<td>Stimulation of IFN-g and CCL3</td>
<td>• IFN-g and CCL3 are key biomarkers of efficacious tumor immunity (Galon J et al, 2006)</td>
</tr>
</tbody>
</table>
Cryo-EM Analysis Demonstrates Location of CMV Antigens in VBI gB/pp65 eVLPs
Mice (n= 4 or 8/group) were immunized at 0 and 4 weeks, and splenocytes harvested 10 days later. Splenocytes from the above groups were stimulated with recombinant CMV gB or pp65 antigens; responses against empty eVLPs were subtracted from all responses. The endpoint titer (EPT) is based on the highest dilution of sera reactive with recombinant gB protein in ELISA with an O.D. of 0.1 or greater.
CMV eVLPs Re-stimulate T-cell Responses & Desired Immunity Profile in CMV-positive Human Subjects *Ex Vivo*

Restimulation of CD4+ & CD8+ T-cells in Ex Vivo Human Samples

Bivalent gB/pp65 eVLPs were used to stimulate freshly isolated PBMCs from 3 healthy subjects. Background responses to empty eVLPs have been subtracted from all data points.
GBM Patient PBMCs Respond to Bivalent CMV eVLP & GM-CSF Stimulation

Bivalent gB/pp65 eVLPs were used to stimulate frozen/thawed PBMCs from 4 healthy subjects and 4 primary GBM patients. CCL3 secretion after stimulation with empty eVLPs has been subtracted from all values.
CMV eVLPs Elicit Responses in PBMCs Obtained From Patients with GBM and Breast Cancer

CCL3 Secretion (pg/ml)

GBM Patient | Breast Cancer Patient

empty eVLPs +GM-CSF

gB/pp65 eVLPs +GM-CSF
Checkpoint Inhibitor (anti-PD-1 mAb) Blockade Enhances CMV eVLP-induced IFN-γ

Increases in CCL3 and IFN-γ secretion are based on 5 healthy CMV+ subjects, comparing gB/pp65 eVLP stimulation in the presence or absence of anti-PD-1 mAb (Opdivo).
Summary

VBI eVLPs Represent a Novel Targeted Approach to Cancer Vaccination

- eVLPs present proteins in a biologically relevant particle & conformation
- Expression of proteins is customizable to optimize desired anti-tumor immunity
- CMV vaccination provides a potent foreign antigenic target with anti-tumor potential & desired biomarker profile
  - Potential application to multiple solid tumors: breast, medulloblastoma, GBM
- eVLP anti-tumor immunity can synergize with checkpoint blockade
Thank You!

VBI Vaccines Inc.
222 Third Street, Suite 2241
Cambridge, MA
02142
info@vbivaccines.com